Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 8/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 7/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2642108 | 1.00 | GCK (0.58) | GCKKCNH2APPPSEN1PSEN2 | |
| SCHEMBL21820635 | 0.93 | GCK (0.66) | GCKKCNH2APPPSEN1PSEN2 | |
| SCHEMBL1860363 | 0.93 | GCK (0.66) | GCKKCNH2APPPSEN1PSEN2 | |
| SCHEMBL2642209 | 0.93 | GCK (0.66) | GCKKCNH2APPPSEN1PSEN2 | |
| SCHEMBL1862621 | 0.93 | GCK (0.66) | GCKKCNH2APPPSEN1PSEN2 | |
| SCHEMBL1862618 | 0.93 | GCK (0.66) | GCKKCNH2APPPSEN1PSEN2 | |
| SCHEMBL1860360 | 0.93 | GCK (0.66) | GCKKCNH2APPPSEN1PSEN2 | |
| SCHEMBL1859324 | 0.90 | KCNH2 (0.60) | GCKKCNH2APPPSEN1PSEN2 | |
| SCHEMBL1171465 | 0.90 | KCNH2 (0.63) | GCKKCNH2APPPSEN1PSEN2 | |
| SCHEMBL1171463 | 0.90 | KCNH2 (0.63) | GCKKCNH2APPPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100567276-C | The amides that three (rings) replace | PROSIDION LTD (GB) | 2009-12-09 | — | — | CN | disclosed |
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | PROSIDION LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-7259166-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| CN-1946702-A | Tri(cyclo) substituted amide compounds | PROSIDION LTD (GB) | 2007-04-11 | — | — | CN | disclosed |
| EP-1740560-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | Prosidion Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| EP-1501815-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | EP | disclosed |
| US-7105671-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060178429-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY L | 2006-08-10 | — | — | US | disclosed |
| WO-2005103021-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | PROSIDION LIMITED (GB) | 2005-11-03 | — | — | WO | disclosed |
| EP-1501815-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003095438-A9 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY LEA (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003095438-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178429-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | GCK 2/4885KCNH2 610/4885APP 2466/4885 |
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | IAPP, GPR119, CPT1A | GCK 86/4885KCNH2 2185/4885APP 1755/4885 |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | GCK 2/4885KCNH2 610/4885APP 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.